Nilotinib for the treatment of chronic myeloid leukemia.
about
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy.
P2860
Nilotinib for the treatment of chronic myeloid leukemia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Nilotinib for the treatment of chronic myeloid leukemia.
@en
type
label
Nilotinib for the treatment of chronic myeloid leukemia.
@en
prefLabel
Nilotinib for the treatment of chronic myeloid leukemia.
@en
P2093
P2860
P356
P1476
Nilotinib for the treatment of chronic myeloid leukemia.
@en
P2093
Bernd Dörken
Philipp le Coutre
Theo Daniel Kim
P2860
P356
10.1586/17474086.1.1.29
P577
2008-10-01T00:00:00Z